Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Nuclear Medicine Market Revenue Outlook: What CAGR Is Expected Through 2030?
The nuclear medicine sector has experienced substantial expansion lately, with projections indicating continued robust growth. This market, valued at $10.18 billion in 2025, is anticipated to reach $11.4 billion by 2026, reflecting a compound annual growth rate of 11.9%. Historically, factors such as constrained availability of nuclear imaging apparatus, elevated expenses associated with radiopharmaceuticals, a deficiency in skilled professionals, underdeveloped infrastructure within hospitals and diagnostic facilities, and diminished public awareness have hampered market penetration.
The nuclear medicine sector is poised for substantial expansion in the coming years, with projections indicating a market value of $17.13 billion by 2030, driven by a compound annual growth rate of 10.7%. This anticipated growth stems from a confluence of factors, including an escalating need for sophisticated diagnostic and therapeutic interventions, augmented governmental support for cancer and cardiovascular health initiatives, a broader integration of nuclear medicine within hospitals and diagnostic facilities, ongoing technological innovations in radiopharmaceuticals and imaging modalities, and an upward trend in patient awareness coupled with increased healthcare spending. Key developments anticipated during this forecast period involve a greater uptake of diagnostic imaging techniques, expanded utilization of therapeutic radiopharmaceuticals, heightened demand for PET and SPECT scans, a pronounced emphasis on applications within oncology and cardiology, and a progressive implementation across healthcare settings like hospitals and specialized diagnostic centers.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7485&type=smp
Nuclear Medicine Market Growth Drivers: What Factors Are Accelerating Expansion?
Anticipated advancements in the nuclear medicine market will be significantly influenced by the escalating rates and occurrence of cardiovascular ailments and malignant growths. These conditions, encompassing heart and circulatory system issues (cardiovascular diseases) and the uncontrolled proliferation and dissemination of aberrant cells (cancer), are becoming more widespread. Nuclear medicine techniques offer substantial benefits, such as expedited diagnosis of cardiac conditions through nuclear cardiac imaging, and effective treatment strategies for cancer, which can be administered alongside or following conventional approaches like surgery and chemotherapy. Consequently, the increasing incidence and prevalence of both cardiovascular diseases and cancer are directly stimulating demand within the nuclear medicine sector. To illustrate, the American Cancer Society Inc., a non-profit health organization in the USA, projected in January 2023 that approximately 1,958,310 new cancer diagnoses would occur in the United States, marking an upward trend from the over 1,918,030 cases identified in 2022. This heightened prevalence of cardiovascular diseases and cancer underscores the market’s upward trajectory.
Nuclear Medicine Market Segment Analysis Highlighting Growth Areas
The nuclear medicine market covered in this report is segmented –
1) By Type: Diagnostic, Therapeutic
2) By Application: Cardiology, Lymphoma, Thyroid, Neurology, Oncology, Other Applications
3) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Diagnostic: Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Gamma Cameras
2) By Therapeutic: Radiopharmaceuticals For Targeted Therapy, Beta Emitters, Alpha Emitters, Radiosynovectomy Agents
Nuclear Medicine Market Trends: What Is Shaping Future Industry Growth?
Key players within the nuclear medicine sector are actively pursuing the creation of groundbreaking technologies, including advanced cyclotrons, to optimize radiopharmaceutical manufacturing and elevate diagnostic imaging quality. Cyclotrons, functioning as sophisticated particle accelerators, are instrumental in generating the radioactive isotopes essential for both medical visualization and therapeutic interventions. They achieve this by bombarding target substances with highly energetic particles, thereby facilitating the creation of radiopharmaceuticals vital for diagnostic techniques like positron emission tomography (PET). Illustrating this trend, GE Healthcare China, a prominent US-based entity in the medical technology sphere, successfully initiated the production of its initial cyclotrons on December 1, 2023, within the Chengdu Tianfu International Bio-Town, marking a significant development in January 2024. The deployment of these cutting-edge accelerators is fundamentally important to the field of nuclear medicine, as they are indispensable for producing the medical isotopes that underpin molecular imaging and various therapeutic applications, ultimately fostering a robust nuclear medicine infrastructure designed to improve early disease identification and the delivery of tailored treatments.
Nuclear Medicine Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the nuclear medicine market are Bracco Imaging S.P.A., Lantheus Medical Imaging Inc., NTP Radioisotopes SOC Ltd., Eckert & Ziegler Group, Jubilant Pharma LLC, Australian Nuclear Science & Technology Organisation, Cardinal Health Inc., GE Healthcare Technologies Inc., Curium Pharma, Advanced Accelerator Applications USA Inc., Nordion Inc., The Institute for Radioelements, Eczacibasi-Monrol Nuclear Products Co., Siemens Healthineers AG, Cambridge Isotope Laboratories Inc., Bayer AG, Triad Isotopes Inc., Mallinckrodt Pharmaceuticals plc, PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., Sinotau Pharmaceuticals Limited, Isotopia Molecular Imaging Limited, SHINE Medical Technologies Inc., JSC Isotope Inc., NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC
Access The Complete Nuclear Medicine Market Report:
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Nuclear Medicine Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the nuclear medicine market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









